# Chronic myeloid leukemia with e6a2 fusion gene: a case report and literature review

## TL;DR

This paper reports a rare case of chronic myeloid leukemia with the e6a2 fusion gene and reviews the literature on its clinical features and treatment response.

## Contribution

The study presents a rare case of CML with e6a2 fusion gene and its response to dasatinib treatment.

## Key findings

- The patient showed complete hematologic and cytogenetic responses after three months of dasatinib treatment.
- e6a2 transcript is rare and more cases are needed to understand its clinical features and improve treatment outcomes.

## Abstract

e6a2转录本类型的慢性髓性白血病（CML）临床上非常罕见，通常与疾病的侵袭有关，其临床特点及与酪氨酸激酶抑制剂疗效间的关系尚不明确。本文通过回顾性分析1例以全身多发溶骨性骨质破坏并胃肠道、淋巴结等多器官嗜酸性粒细胞浸润为特征的e6a2融合基因阳性CML患者的临床特点及相关实验室检查，并进行相关文献复习。该患者Ph染色体阳性，伴+8染色体，CML常见BCR::ABL1转录本均阴性，但通过RT-PCR检测出e6a2转录本阳性表达，予以达沙替尼100 mg/d治疗，3个月后复查达到了完全血液学反应、完全细胞遗传学反应及分子学反应4.0。e6a2转录本在临床上非常罕见，需研究更多e6a2转录本的病例以明确其临床特点，并改善这些罕见病例的治疗效果。